Xiaobin Cui Selected Research

phospholipase C epsilon

1/2021	Identification of a PLCE1‑regulated competing endogenous RNA regulatory network for esophageal squamous cell carcinoma.
1/2020	Hypomethylation-Linked Activation of PLCE1 Impedes Autophagy and Promotes Tumorigenesis through MDM2-Mediated Ubiquitination and Destabilization of p53.
5/2018	Comprehensive bioinformation analysis of the miRNA of PLCE1 knockdown in esophageal squamous cell carcinoma.
11/2017	Comprehensive bioinformatics analysis of the mRNA profile of PLCE1 knockdown in esophageal squamous cell carcinoma.
4/2014	Heterozygote of PLCE1 rs2274223 increases susceptibility to human papillomavirus infection in patients with esophageal carcinoma among the Kazakh populations.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xiaobin Cui Research Topics

Disease

23	Neoplasms (Cancer) 01/2022 - 01/2014
9	Esophageal Squamous Cell Carcinoma 01/2021 - 01/2015
6	Carcinogenesis 01/2021 - 01/2014
5	Esophageal Neoplasms (Esophageal Cancer) 03/2020 - 04/2014
3	Carcinoma (Carcinomatosis) 03/2020 - 05/2015
2	Synovial Sarcoma (Synovioma) 10/2019 - 01/2017
1	Neoplasm Metastasis (Metastasis) 12/2020
1	Colonic Neoplasms (Colon Cancer) 12/2020
1	Breast Neoplasms (Breast Cancer) 02/2019
1	Disease Progression 01/2019
1	Inflammation (Inflammations) 11/2017
1	Infections 01/2016
1	Lymphatic Metastasis 01/2016
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2016
1	Head and Neck Neoplasms (Head and Neck Cancer) 01/2016
1	Sarcoma (Soft Tissue Sarcoma) 01/2015
1	Rhabdomyosarcoma 01/2014

Drug/Important Bio-Agent (IBA)

8	MicroRNAs (MicroRNA)IBA 01/2019 - 01/2015
7	Biomarkers (Surrogate Marker)IBA 01/2021 - 05/2015
5	phospholipase C epsilonIBA 01/2021 - 04/2014
4	ParaffinIBA 10/2019 - 01/2014
3	Proteins (Proteins, Gene)FDA Link 01/2019 - 01/2014
3	Formaldehyde (Formol)FDA Link 01/2019 - 01/2014
3	VimentinIBA 01/2015 - 01/2014
2	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 01/2017
2	3-hydroxy-5-estrane-17-carbonitrile (ACN)IBA 01/2019 - 10/2014
2	Messenger RNA (mRNA)IBA 11/2017 - 08/2017
1	Biotin (Vitamin H)FDA Link 01/2022
1	Competitive Endogenous RNAIBA 01/2021
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 12/2020
1	Fibronectins (Fibronectin)IBA 03/2020
1	OsteopontinIBA 03/2020
1	Histone Acetyltransferases (Histone Acetyltransferase)IBA 10/2019
1	Carrier Proteins (Binding Protein)IBA 10/2019
1	Paclitaxel (Taxol)FDA LinkGeneric 02/2019
1	Betulinic AcidIBA 02/2019
1	Vascular Endothelial Growth Factor CIBA 01/2019
1	Oncogene Proteins (Oncogene Protein)IBA 01/2019
1	Oxygen (Dioxygen)IBA 01/2019
1	ChemokinesIBA 11/2017
1	LigandsIBA 11/2017
1	Matrix Metalloproteinases (MMPs)IBA 07/2017
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2017
1	Cyclin-Dependent Kinase Inhibitor p16IBA 01/2016
1	transporter associated with antigen processing (TAP)IBA 07/2015
1	EpitopesIBA 10/2014
1	HLA-DQB1 antigen (HLA DQB1)IBA 10/2014
1	HLA Antigens (Human Leukocyte Antigens)IBA 10/2014
1	HLA-DRB1 Chains (HLA DRB1)IBA 10/2014
1	MART-1 AntigenIBA 01/2014
1	Mucin-1 (CA 15-3 Antigen)IBA 01/2014
1	Guanine Nucleotide Exchange Factors (Guanine Nucleotide Exchange Factor)IBA 01/2014
1	Collagen Type IV (Type IV Collagen)IBA 01/2014
1	AntigensIBA 01/2014
1	CalponinsIBA 01/2014

Therapy/Procedure

4	Therapeutics 01/2022 - 01/2019
1	Drug Therapy (Chemotherapy) 01/2022
1	Photothermal Therapy 01/2022
1	Immunotherapy 01/2021